AGIO

Vorasidenib (IDH1/IDH2 inhibitor)

Low-Grade Glioma

Phase 3 to be Initiated

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links


TITLE: Vorasidenib for Low-Grade Glioma Phase 3 to be Initiated

  • Clinical Trial (NCT04164901) Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

WHAT IS THE NEXT CATALYST EVENT?

  • Phase 3 To be Initiated


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD 


PRIOR DATA/EVENTS

PRESS RELEASES

MECHANISM OF ACTION

  • Vorasidenib is an investigational, orally available, selective dual inhibitor of the mutated IDH1 and IDH2 proteins.

  • In early clinical studies, vorasidenib demonstrated full blood-brain barrier penetrance, robust suppression of the oncometabolite 2-HG and encouraging preliminary efficacy. Vorasidenib is currently being studied in the registration-enabling Phase 3 INDIGO study in patients with IDH-mutant low-grade glioma.

Updated by MV

IDH1, IDH2, GLioma, low-grade glioma, AGIO, Agios, vorasidenib 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon